The North America Orthopedic Regenerative Surgical Products Market would witness market growth of 3.7% CAGR during the forecast period (2023-2030).
The workings of crucial pathways for regeneration and healing have been dramatically unveiled by fundamental advancements in basic research. Various primary and supplementary regeneration therapies are becoming more accessible, including preparations generated from bone marrow, growth hormones, and stem cells. Clinical practice is being transformed by supporting therapies that are efficient both during the index surgery and the postoperative period in the latest phase of biologically active material application. Regenerative therapies are now being improved in many facets of orthopedic surgery to improve success and outcomes.
Regenerative orthopedics can lessen discomfort and pain in the musculoskeletal structures and speed up the recovery from orthopedic disorders like injuries to the tendons, ligaments, bones, muscles, and meniscus. As these are unable to repair themselves, these tissues can mend more quickly because of regenerative therapy. Certain degenerative disorders, such as arthritis and sports injuries, can be treated using regenerative orthopedics or orthobiologics. Regenerative medicine may enable some patients to postpone their requirement for orthopedic surgery.
When used to treat early stages of arthritis, such as early knee osteoarthritis, or tendinopathies like tennis elbow (lateral epicondylitis), biologic therapy has shown promise and may help postpone surgery. These can also help the body mend following surgery to repair particular tendons, such as the rotator cuff, and address avascular necrosis (death of bone tissue brought on by a short- or long-term absence of blood supply to the bone).
In the United States, an estimated 58.5 million persons have arthritis, which is much more common in women than men, according to statistics from the Centers for Disease Control and Prevention (CDC) from 2023. Additionally, 78.4 million, or about 25.9% of the estimated adult population, persons aged 18 and older will have arthritis officially diagnosed by a doctor by 2040, according to the CDC. Furthermore, North America's market has experienced tremendous growth due to the high awareness of these products and the high prevalence of arthritis joint pain among adults in the United States, along with other co-occurring conditions like diabetes. Hence, the region presents lucrative growth prospects for the market.
The US market dominated the North America Orthopedic Regenerative Surgical Products Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $1,534.2 million by 2030. The Canada market is experiencing a CAGR of 6.1% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 5.1% during (2023 - 2030).
Based on End-Use, the market is segmented into Hospitals, Ambulatory Surgical Centers and Others. Based on Application, the market is segmented into Joint Reconstruction, Cartilage & Tendon Repair, Trauma Repair, Orthopedic Pain Management and Others. Based on Product, the market is segmented into Viscosupplements, Allografts (Amniotic Products and Others), Synthetic and Cell-based. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Worldwide Orthopedic Regenerative Surgical Products Market is Projected to reach USD 5.4 Billion by 2030, at a CAGR of 4.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include MiMedx Group, Inc., Vericel Corporation, Baxter International, Inc., Zimmer Biomet Holdings, Inc., Stryker Corporation, Smith & Nephew, Arthrex, Inc., BioTissue Holdings, Inc., VSY Biotechnology GmbH and Aptissen S.A.
By End-use
By Application
By Product
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 